Activation of β-catenin/TCF targets following loss of the tumor suppressor SNF5

Oncogene

Volumn 33, Issue 7, 2014, Pages 933-938

  Mora Blanco, E L ^a,b,d   Mishina, Y ^c   Tillman, E J ^a,b   Cho, Y J ^b,e   Thom, C S ^a,b,f   Pomeroy, S L ^b   Shao, W ^c   Roberts, C W M ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^d LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

beta catenin; chromatin remodeling; epigenetics; Swi Snf; tumor suppressor

Indexed keywords

ANIMALS; BASE SEQUENCE; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; CHROMOSOMAL PROTEINS, NON-HISTONE; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MEDULLOBLASTOMA; MICE; MICE, TRANSGENIC; REAL-TIME POLYMERASE CHAIN REACTION; RHABDOID TUMOR; RNA, MESSENGER; TRANSCRIPTION FACTORS; TRANSCRIPTOME; TUMOR CELLS, CULTURED; WNT SIGNALING PATHWAY;

EID: 84894107169     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.37     Document Type: Article

References (38)

1. de la Serna IL, Ohkawa Y, Imbalzano AN. Chromatin remodelling in mammalian differentiation: lessons from ATP-dependent remodellers. Nat Rev Genet 2006; 7: 461-473.
2. Ho L, Crabtree GR. Chromatin remodelling during development. Nature 2010; 463: 474-484.
3. Wilson BG, Roberts CW. SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer 2011; 11: 481-492.
4. Roberts CW, Galusha SA, McMenamin ME, Fletcher CD, Orkin SH. Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice. Proc Natl Acad Sci USA 2000; 97: 13796-13800.
5. Klochendler-Yeivin A, Fiette L, Barra J, Muchardt C, Babinet C, Yaniv M. The murine SNF5/INI1 chromatin remodeling factor is essential for embryonic development and tumor suppression. EMBO Rep 2000; 1: 500-506.
6. Guidi CJ, Sands AT, Zambrowicz BP, Turner TK, Demers DA, Webster W et al. Disruption of Ini1 leads to peri-implantation lethality and tumorigenesis in mice. Mol Cell Biol 2001; 21: 3598-3603.
7. Versteege I, Sévenet N, Lange J, Rousseau-Merck MF, Ambros P, Handgretinger R et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 1998; 394: 203-206.
8. Biegel JA, Zhou JY, Rorke LB, Stenstrom C, Wainwright LM, Fogelgren B. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res 1999; 59: 74-79.
9. Roberts CWM, Leroux MM, Fleming MD, Orkin SH. Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5. Cancer Cell 2002; 2: 415-425.
10. McKenna ES, Sansam CG, Cho Y-J, Greulich H, Evans JA, Thom CS et al. Loss of the epigenetic tumor suppressor SNF5 leads to cancer without genomic instability. Mol Cell Biol 2008; 28: 6223-6233.
11. McKenna ES, Roberts CW. Epigenetics and cancer without genomic instability. Cell Cycle 2009; 8: 23-26.
12. Gresh L, Bourachot B, Reimann A, Guigas B, Fiette L, Garbay S et al. The SWI/SNF chromatin-remodeling complex subunit SNF5 is essential for hepatocyte differentiation. EMBO J. 2005; 24: 3313-3324.
13. Wilson BG, Wang X, Shen X, Mckenna ES, Lemieux ME, Cho Y-J et al. Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell 2010; 18: 316-328.
14. Jagani Z, Mora-Blanco EL, Sansam CG, McKenna ES, Wilson B, Chen D et al. Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway. Nat Med 2010; 16: 1429-1433.
15. Griffin CT, Curtis CD, Davis RB, Muthukumar V, Magnuson T. The chromatinremodeling enzyme BRG1 modulates vascular Wnt signaling at two levels. Proc Natl Acad Sci USA 2011; 108: 2282-2287.
16. Park J-I, Venteicher AS, Hong JY, Choi J, Jun S, Shkreli M et al. Telomerase modulates Wnt signalling by association with target gene chromatin. Nature 2009; 460: 66-72.
17. Curtis CD, Griffin CT. The chromatin-remodeling enzymes BRG1 and CHD4 antagonistically regulate vascular Wnt signaling. Mol Cell Biol 2012; 32: 1312-1320.
18. Mahmoudi T, Boj SF, Hatzis P, Li VS, Taouatas N, Vries RG et al. The leukemiaassociated Mllt10/Af10-Dot1l are Tcf4/beta-catenin coactivators essential for intestinal homeostasis. PLoS Biol 2010; 8: e1000539.
19. Logan M, Martin JF, Nagy A, Lobe C, Olson EN, Tabin CJ. Expression of Cre Recombinase in the developing mouse limb bud driven by a Prxl enhancer. Genesis 2002; 33: 77-80.
20. Hill TP, Später D, Taketo MM, Birchmeier W, Hartmann C. Canonical Wnt/betacatenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev Cell 2005; 8: 727-738.
21. Hill TP, Taketo MM, Birchmeier W, Hartmann C. Multiple roles of mesenchymal beta-catenin during murine limb patterning. Development 2006; 133: 1219-1229.
22. Chien AJ, Conrad WH, Moon RT. A Wnt survival guide: from flies to human disease. J Invest Dermatol 2009; 129: 1614-1627.
23. DasGupta R, Fuchs E. Multiple roles for activated LEF/TCF transcription complexes during hair follicle development and differentiation. Development 1999; 126: 4557-4568.
24. Cho YJ, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich H et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol 2011; 29: 1424-1430.
25. Oruetxebarria I, Venturini F, Kekarainen T, Houweling A, Zuijderduijn LMP, Mohd-Sarip A et al. P16INK4a is required for hSNF5 chromatin remodeler-induced cellular senescence in malignant rhabdoid tumor cells. J Biol Chem 2004; 279: 3807-3816.
26. Ettenberg SA, Charlat O, Daley MP, Liu S, Vincent KJ, Stuart DD et al. Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies. Proc Natl Acad Sci USA 2010; 107: 15473-15478.
27. Huang S-MA, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009; 461: 614-620.
28. Miller KA, Barrow J, Collinson JM, Davidson S, Lear M, Hill RE et al. A highly conserved Wnt-dependent TCF4 binding site within the proximal enhancer of the anti-myogenic Msx1 gene supports expression within Pax3-expressing limb bud muscle precursor cells. Dev Biol 2007; 311: 665-678.
29. Hu MC, Rosenblum ND. Smad1, beta-catenin and Tcf4 associate in a molecular complex with the Myc promoter in dysplastic renal tissue and cooperate to control Myc transcription. Development 2005; 132: 215-225.
30. Bottomly D, Kyler SL, McWeeney SK, Yochum GS. Identification of {beta}-catenin binding regions in colon cancer cells using ChIP-Seq. Nucleic Acids Res 2010; 38: 5735-5745.
31. Collins RT, Treisman JE. Osa-containing Brahma chromatin remodeling complexes are required for the repression of wingless target genes. Genes Dev 2000; 14: 3140-3152.
32. Barker N, Hurlstone A, Musisi H, Miles A, Bienz M, Clevers H. The chromatin remodelling factor Brg-1 interacts with beta-catenin to promote target gene activation. EMBO J. 2001; 20: 4935-4943.
33. Chi TH, Wan M, Lee PP, Akashi K, Metzger D, Chambon P et al. Sequential roles of Brg, the ATPase subunit of BAF chromatin remodeling complexes, in thymocyte development. Immunity 2003; 19: 169-182.
34. Robinson G, Parker M, Kranenburg TA, Lu C, Chen X, Ding L et al. Novel mutations target distinct subgroups of medulloblastoma. Nature 2012; 488: 43-48.
35. Lee RS, Stewart C, Carter SL, Ambrogio L, Cibulskis K, Sougnez C et al. A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. J Clin Invest 2012; 122: 2983-2988.
36. Ngo-Muller V, Muneoka K. Influence of FGF4 on digit morphogenesis during limb development in the mouse. Dev Biol 2000; 219: 224-236.
37. Schaefer CF, Anthony K, Krupa S, Buchoff J, Day M, Hannay T et al. PID: the Pathway Interaction Database. Nucleic Acids Res. 2009; 37(Database issue): D674-D679.
38. Willert J, Epping M, Pollack JR, Brown PO, Nusse R. A transcriptional response to Wnt protein in human embryonic carcinoma cells. BMC Dev Biol 2002; 2: 8.